# Ann K Daly

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 301 papers | 23,440 citations | 79 h-index | 147 g-index |
| 324 ext. papers | 26,235 ext. citations | 8.3 avg, IF | 6.72 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 301 | Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nature Genetics*, **2001**, 27, 383-91 | 36.3 | 1738 |
| 300 | Estimation of the warfarin dose with clinical and pharmacogenetic data. *New England Journal of Medicine*, **2009**, 360, 753-64 | 59.2 | 1161 |
| 299 | Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. *Lancet, The*, **1999**, 353, 717-9 | 40 | 1066 |
| 298 | HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nature Genetics*, **2009**, 41, 816-9 | 36.3 | 818 |
| 297 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. *Blood*, **2005**, 106, 2329-33 | 2.2 | 799 |
| 296 | A randomized trial of genotype-guided dosing of warfarin. *New England Journal of Medicine*, **2013**, 369, 2294-303 | 59.2 | 617 |
| 295 | Case definition and phenotype standardization in drug-induced liver injury. *Clinical Pharmacology and Therapeutics*, **2011**, 89, 806-15 | 6.1 | 563 |
| 294 | Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*, **2010**, 51, 1209-17 | 11.2 | 445 |
| 293 | TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nature Communications*, **2014**, 5, 4309 | 17.4 | 362 |
| 292 | Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology*, **2011**, 141, 338-47 | 13.3 | 359 |
| 291 | Nomenclature for human CYP2D6 alleles. *Pharmacogenetics and Genomics*, **1996**, 6, 193-201 | | 348 |
| 290 | Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. *Journal of Hepatology*, **2014**, 61, 75-81 | 13.4 | 310 |
| 289 | Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. *Clinical Pharmacology and Therapeutics*, **2005**, 77, 468-78 | 6.1 | 287 |
| 288 | Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. *Hepatology*, **1997**, 26, 143-6 | 11.2 | 279 |
| 287 | Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. *Gastroenterology*, **2007**, 132, 272-81 | 13.3 | 277 |
| 286 | The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. *Pharmacogenetics and Genomics*, **2001**, 11, 555-72 | | 269 |
| 285 | Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. *Pharmacogenetics and Genomics*, **2002**, 12, 121-32 | | 268 |

| | | | |
|---|---|---|---|
| 284 | Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. *Pharmacogenetics and Genomics*, **1995**, 5, 215-23 | | 230 |
| 283 | Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. *Carcinogenesis*, **2002**, 23, 1343-50 | 4.6 | 228 |
| 282 | Mutant debrisoquine hydroxylation genes in Parkinson's disease. *Lancet, The*, **1992**, 339, 1017-8 | 40 | 221 |
| 281 | Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. *Transplantation*, **2003**, 76, 1233-5 | 1.8 | 210 |
| 280 | Genome-wide association studies in pharmacogenomics. *Nature Reviews Genetics*, **2010**, 11, 241-6 | 30.1 | 209 |
| 279 | CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. *Biochemical Pharmacology*, **2002**, 64, 1579-89 | 6 | 207 |
| 278 | The role of individual human cytochromes P450 in drug metabolism and clinical response. *Trends in Pharmacological Sciences*, **1992**, 13, 434-9 | 13.2 | 202 |
| 277 | Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. *Neuropsychopharmacology*, **2002**, 27, 105-19 | 8.7 | 193 |
| 276 | Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. *Hepatology*, **2004**, 39, 1430-40 | 11.2 | 188 |
| 275 | Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. *Hepatology*, **2013**, 57, 727-39 | 11.2 | 182 |
| 274 | Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. *Hepatology*, **1998**, 27, 1695-9 | 11.2 | 173 |
| 273 | Significance of the minor cytochrome P450 3A isoforms. *Clinical Pharmacokinetics*, **2006**, 45, 13-31 | 6.2 | 170 |
| 272 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature*, **2021**, 592, 450-456 | 50.4 | 164 |
| 271 | CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. *Journal of the National Cancer Institute*, **1997**, 89, 1207-12 | 9.7 | 162 |
| 270 | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 204-12 | 6.1 | 162 |
| 269 | Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. *American Journal of Epidemiology*, **2002**, 156, 95-109 | 3.8 | 159 |
| 268 | Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. *FEBS Letters*, **1996**, 392, 30-4 | 3.8 | 159 |
| 267 | Metabolic polymorphisms **1993**, 57, 129-60 | | 159 |

| | | | |
|---|---|---|---|
| 266 | CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. *Journal of Hepatology*, **2000**, 32, 538-41 | 13.4 | 157 |
| 265 | Pharmacogenetics of oral anticoagulants. *Pharmacogenetics and Genomics*, **2003**, 13, 247-52 | | 156 |
| 264 | CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 422-33 | 6.1 | 150 |
| 263 | Pharmacogenetics of the major polymorphic metabolizing enzymes. *Fundamental and Clinical Pharmacology*, **2003**, 17, 27-41 | 3.1 | 147 |
| 262 | Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. *Gastroenterology*, **2017**, 152, 1078-1089 | 13.3 | 137 |
| 261 | Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. *Clinical Pharmacology and Therapeutics*, **2003**, 74, 380-7 | 6.1 | 136 |
| 260 | Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. *Pharmacogenetics and Genomics*, **2000**, 10, 11-24 | | 128 |
| 259 | Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. *Biochemical Pharmacology*, **2000**, 60, 517-26 | 6 | 127 |
| 258 | The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. *Journal of Hepatology*, **2012**, 56, 448-54 | 13.4 | 126 |
| 257 | Genetic variation of CYP2A6, smoking, and risk of cancer. *Lancet, The*, **1999**, 353, 898-9 | 40 | 126 |
| 256 | Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. *Gut*, **2000**, 46, 540-5 | 19.2 | 125 |
| 255 | Candidate gene case-control association studies: advantages and potential pitfalls. *British Journal of Clinical Pharmacology*, **2001**, 52, 489-99 | 3.8 | 118 |
| 254 | Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. *Gut*, **2010**, 59, 267-73 | 19.2 | 117 |
| 253 | Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. *Pharmacogenomics*, **2009**, 10, 1687-95 | 2.6 | 115 |
| 252 | Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. *Journal of Hepatology*, **2010**, 53, 1049-53 | 13.4 | 114 |
| 251 | Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. *Journal of Hepatology*, **2020**, 73, 505-515 | 13.4 | 113 |
| 250 | CYP2D6 multiallelism. *Methods in Enzymology*, **1996**, 272, 199-210 | 1.7 | 109 |
| 249 | Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. *Journal of the National Cancer Institute*, **1995**, 87, 1246-53 | 9.7 | 103 |

| | | | |
|---|---|---|---|
| 248 | Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. *Diabetologia*, **1998**, 41, 430-4 | 10.3 | 102 |
| 247 | Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. *Biochemical Pharmacology*, **1994**, 47, 1157-63 | 6 | 101 |
| 246 | Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. *Clinical Pharmacology and Therapeutics*, **2016**, 99, 172-85 | 6.1 | 100 |
| 245 | CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. *Pharmacogenetics and Genomics*, **1998**, 8, 529-41 | | 99 |
| 244 | Pharmacogenetics of the cytochromes P450. *Current Topics in Medicinal Chemistry*, **2004**, 4, 1733-44 | 3 | 99 |
| 243 | Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 158-65 | 14.6 | 98 |
| 242 | Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. *Pharmacogenetics and Genomics*, **1991**, 1, 33-41 | | 98 |
| 241 | Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. *British Journal of Clinical Pharmacology*, **2014**, 77, 626-41 | 3.8 | 97 |
| 240 | Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. *Pharmacogenetics and Genomics*, **2012**, 22, 784-95 | 1.9 | 96 |
| 239 | Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. *Pharmacogenetics and Genomics*, **2000**, 10, 511-8 | | 96 |
| 238 | Genetic basis of drug-induced liver injury: present and future. *Seminars in Liver Disease*, **2014**, 34, 123-33 | 7.3 | 95 |
| 237 | Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. *Carcinogenesis*, **1997**, 18, 1351-4 | 4.6 | 93 |
| 236 | Detection and characterization of novel polymorphisms in the CYP2E1 gene. *Pharmacogenetics and Genomics*, **1998**, 8, 543-52 | | 93 |
| 235 | Genetics of alcoholic and nonalcoholic fatty liver disease. *Seminars in Liver Disease*, **2011**, 31, 128-46 | 7.3 | 91 |
| 234 | Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. *Pharmacogenetics and Genomics*, **2001**, 11, 45-55 | | 91 |
| 233 | PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. *American Journal of Gastroenterology*, **2015**, 110, 846-56 | 0.7 | 90 |
| 232 | VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. *Blood*, **2012**, 119, 868-73 | 2.2 | 88 |
| 231 | An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. *Pharmacogenetics and Genomics*, **1998**, 8, 129-35 | | 88 |

| | | | |
|---|---|---|---|
| 230 | Genetic association studies in drug-induced liver injury. *Seminars in Liver Disease*, **2009**, 29, 400-11 | 7.3 | 87 |
| 229 | Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. *Journal of Personalized Medicine*, **2017**, 8, | 3.6 | 86 |
| 228 | Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. *British Journal of Psychiatry*, **1997**, 170, 23-6 | 5.4 | 86 |
| 227 | The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. *Pharmacogenetics and Genomics*, **1998**, 8, 335-42 | | 84 |
| 226 | Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. *Drug Metabolism Reviews*, **1999**, 31, 467-87 | 7 | 83 |
| 225 | Using genome-wide association studies to identify genes important in serious adverse drug reactions. *Annual Review of Pharmacology and Toxicology*, **2012**, 52, 21-35 | 17.9 | 82 |
| 224 | Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. *Pharmacogenetics and Genomics*, **2004**, 14, 813-22 | | 82 |
| 223 | Genetic association studies in drug-induced liver injury. *Drug Metabolism Reviews*, **2012**, 44, 116-26 | 7 | 79 |
| 222 | Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. *Journal of Hepatology*, **2017**, 67, 137-144 | 13.4 | 78 |
| 221 | Characterization of amoxicillin and clavulanic-acid-responsive CD4+ And CD8+ T-cells in patients with co-amoxiclav-induced liver injury. *Clinical and Translational Allergy*, **2014**, 4, P42 | 5.2 | 78 |
| 220 | Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. *European Heart Journal*, **2011**, 32, 1909-17 | 9.5 | 78 |
| 219 | Pharmacogenetics and human genetic polymorphisms. *Biochemical Journal*, **2010**, 429, 435-49 | 3.8 | 78 |
| 218 | CYP3A5 phenotype-genotype correlations in a British population. *British Journal of Clinical Pharmacology*, **2004**, 57, 664-664 | 3.8 | 78 |
| 217 | Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. *Gut*, **1998**, 43, 262-6 | 19.2 | 74 |
| 216 | Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. *International Journal of Cancer*, **2001**, 92, 777-83 | 7.5 | 73 |
| 215 | Pharmacogenomics of adverse drug reactions. *Genome Medicine*, **2013**, 5, 5 | 14.4 | 72 |
| 214 | Evidence that a polymorphism within the 3′UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. *Genes and Nutrition*, **2007**, 2, 225-32 | 4.3 | 71 |
| 213 | Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. *Archives of Toxicology*, **2002**, 76, 643-9 | 5.8 | 71 |

| | | | |
|---|---|---|---|
| 212 | Molecular basis of polymorphic drug metabolism. *Journal of Molecular Medicine*, **1995**, 73, 539-53 | 5.5 | 71 |
| 211 | Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. *Journal of Hepatology*, **1999**, 30, 232-6 | 13.4 | 70 |
| 210 | Interphase nuclear matrix and metaphase scaffolding structures. *Journal of Cell Science*, **1984**, 1, 103-22 | 5.3 | 70 |
| 209 | Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. *Hepatology*, **2015**, 62, 887-99 | 11.2 | 67 |
| 208 | Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. *Journal of Investigative Dermatology*, **2011**, 131, 1981-6 | 4.3 | 66 |
| 207 | Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology*, **2020**, 73, 252-262 | 13.4 | 65 |
| 206 | The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. *Journal of Hepatology*, **2011**, 55, 1409-14 | 13.4 | 65 |
| 205 | Drug-induced liver injury: past, present and future. *Pharmacogenomics*, **2010**, 11, 607-11 | 2.6 | 65 |
| 204 | Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. *Lung Cancer*, **2000**, 28, 147-55 | 5.9 | 62 |
| 203 | Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. *Pharmacogenetics and Genomics*, **1996**, 6, 527-33 | | 62 |
| 202 | Oral anticoagulation: a critique of recent advances and controversies. *Trends in Pharmacological Sciences*, **2015**, 36, 153-63 | 13.2 | 60 |
| 201 | Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. *Pharmacogenetics and Genomics*, **2000**, 10, 91-3 | | 60 |
| 200 | A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. *Gastroenterology*, **2019**, 156, 1707-1716.e2 | 13.3 | 59 |
| 199 | Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. *Annals of the Rheumatic Diseases*, **2010**, 69, 1315-20 | 2.4 | 59 |
| 198 | Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. *Human Molecular Genetics*, **2000**, 9, 1563-6 | 5.6 | 59 |
| 197 | TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?. *Gastroenterology*, **2015**, 148, 679-84 | 13.3 | 58 |
| 196 | The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. *Clinical Pharmacology and Therapeutics*, **2011**, 89, 784-5 | 6.1 | 58 |
| 195 | The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. *British Journal of Clinical Pharmacology*, **2012**, 73, 66-76 | 3.8 | 57 |

| | | | |
|---|---|---|---|
| 194 | Genetic modifiers of non-alcoholic fatty liver disease progression. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2011**, 1812, 1557-66 | 6.9 | 54 |
| 193 | Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. *Clinica Chimica Acta*, **2013**, 416, 11-9 | 6.2 | 52 |
| 192 | Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. *Carcinogenesis*, **1997**, 18, 1203-14 | 4.6 | 52 |
| 191 | The pharmacogenetics of chemical carcinogenesis. *Pharmacogenetics and Genomics*, **1992**, 2, 246-58 | | 52 |
| 190 | Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. *Hepatology*, **2003**, 37, 410-9 | 11.2 | 51 |
| 189 | Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. *Science Translational Medicine*, **2020**, 12, | 17.5 | 51 |
| 188 | A role for the pregnane X receptor in flucloxacillin-induced liver injury. *Hepatology*, **2010**, 51, 1656-64 | 11.2 | 50 |
| 187 | CYP3A5 phenotype-genotype correlations in a British population. *British Journal of Clinical Pharmacology*, **2003**, 55, 625-9 | 3.8 | 50 |
| 186 | Poor metabolisers of nicotine and CYP2D6 polymorphism. *Lancet, The*, **1994**, 343, 62-3 | 40 | 50 |
| 185 | HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. *Pharmacogenetics and Genomics*, **2016**, 26, 218-24 | 1.9 | 50 |
| 184 | Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. *Pharmacogenetics and Genomics*, **2009**, 19, 800-12 | 1.9 | 49 |
| 183 | N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. *European Journal of Clinical Pharmacology*, **2014**, 70, 1079-86 | 2.8 | 48 |
| 182 | Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. *Expert Review of Gastroenterology and Hepatology*, **2011**, 5, 253-63 | 4.2 | 48 |
| 181 | Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. *Pharmacogenetics and Genomics*, **1996**, 6, 319-28 | | 47 |
| 180 | The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. *Pharmacogenetics and Genomics*, **1994**, 4, 73-81 | | 47 |
| 179 | Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. *Toxicology Letters*, **1998**, 102-103, 143-7 | 4.4 | 45 |
| 178 | Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. *Pharmacogenetics and Genomics*, **1999**, 9, 367-75 | | 45 |
| 177 | Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. *Pharmacogenetics and Genomics*, **1996**, 6, 151-8 | | 45 |

| | | | |
|---|---|---|---|
| 176 | Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. *Archives of Toxicology*, **2013**, 87, 407-20 | 5.8 | 44 |
| 175 | Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. *Cell Cycle*, **2014**, 13, 1489-94 | 4.7 | 44 |
| 174 | CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease. *Pharmacogenetics and Genomics*, **1999**, 9, 31-5 | | 43 |
| 173 | APOE genotype makes a small contribution to warfarin dose requirements. *Pharmacogenetics and Genomics*, **2006**, 16, 609-11 | 1.9 | 42 |
| 172 | Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. *Toxicology Research*, **2018**, 7, 347-357 | 2.6 | 41 |
| 171 | Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. *Pharmacogenetics and Genomics*, **1999**, 9, 327-32 | | 41 |
| 170 | Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **1996**, 55, 66-8 | 2.4 | 41 |
| 169 | Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. *Genes and Immunity*, **2001**, 2, 44-7 | 4.4 | 40 |
| 168 | Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. *Hepatology*, **2002**, 36, 1355-1360 | 11.2 | 39 |
| 167 | Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. *Digestive Diseases and Sciences*, **2001**, 46, 1520-5 | 4 | 39 |
| 166 | Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. *Clinical Cancer Research*, **2013**, 19, 469-79 | 12.9 | 37 |
| 165 | A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. *Clinical Science*, **2011**, 120, 287-96 | 6.5 | 37 |
| 164 | Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 245-253 | 6.1 | 35 |
| 163 | Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype. *British Journal of Nutrition*, **2010**, 103, 1585-93 | 3.6 | 35 |
| 162 | Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. *International Journal of Neuropsychopharmacology*, **2000**, 3, 61-65 | 5.8 | 35 |
| 161 | Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1028-1036 | 6.1 | 34 |
| 160 | Stereoselective cardiotoxic effects of terodiline. *Clinical Pharmacology and Therapeutics*, **1996**, 60, 89-98 | 6.1 | 34 |
| 159 | Polygenic architecture informs potential vulnerability to drug-induced liver injury. *Nature Medicine*, **2020**, 26, 1541-1548 | 50.5 | 34 |

| | | | |
|---|---|---|---|
| 158 | Characterisation of a retinoic-acid-binding component from F9 embryonal-carcinoma-cell nuclei. *FEBS Journal*, **1987**, 168, 133-9 | | 33 |
| 157 | A multi-factorial analysis of response to warfarin in a UK prospective cohort. *Genome Medicine*, **2016**, 8, 2 | 14.4 | 32 |
| 156 | Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?. *Archives of Toxicology*, **2003**, 77, 313-20 | 5.8 | 32 |
| 155 | Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. *Cell Biochemistry and Function*, **2005**, 23, 73-6 | 4.2 | 32 |
| 154 | Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. *Pharmacogenetics and Genomics*, **1995**, 5, 234-43 | | 32 |
| 153 | Promiscuous T-cell responses to drugs and drug-haptens. *Journal of Allergy and Clinical Immunology* , **2015**, 136, 474-6.e8 | 11.5 | 31 |
| 152 | CYP2D6 deficiency, a factor in ecstasy related deaths?. *British Journal of Clinical Pharmacology*, **2002**, 54, 69-70 | 3.8 | 31 |
| 151 | Inter-individual variation in nucleotide excision repair in young adults: effects of age, adiposity, micronutrient supplementation and genotype. *British Journal of Nutrition*, **2009**, 101, 1316-23 | 3.6 | 30 |
| 150 | Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. *Pharmacogenetics and Genomics*, **1997**, 7, 401-4 | | 30 |
| 149 | No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. *Journal of Hepatology*, **1998**, 28, 820-3 | 13.4 | 30 |
| 148 | Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases. *Advances in Pharmacology*, **2015**, 74, 85-111 | 5.7 | 29 |
| 147 | Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. *Cancer Medicine*, **2017**, 6, 1930-1940 | 4.8 | 29 |
| 146 | Genetics of Alcoholic Liver Disease. *Seminars in Liver Disease*, **2015**, 35, 361-74 | 7.3 | 29 |
| 145 | Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohnß disease. *Gut*, **2005**, 54, 1579-84 | 19.2 | 29 |
| 144 | Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon probes. *Clinica Chimica Acta*, **2011**, 412, 2063-9 | 6.2 | 28 |
| 143 | An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. *Human Genetics*, **1995**, 95, 337-41 | 6.3 | 28 |
| 142 | Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?. *Pharmaceutical Research*, **2017**, 34, 1564-1569 | 4.5 | 27 |
| 141 | Pharmacogenomics of anticoagulants: steps toward personal dosage. *Genome Medicine*, **2009**, 1, 10 | 14.4 | 27 |

| | | | |
|---|---|---|---|
| 140 | Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. *Postgraduate Medical Journal*, **2004**, 80, 107-9 | 2 | 27 |
| 139 | PharmVar GeneFocus: CYP2C19. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 352-366 | 6.1 | 27 |
| 138 | Pharmacogenetics: a general review on progress to date. *British Medical Bulletin*, **2017**, 124, 65-79 | 5.4 | 26 |
| 137 | Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. *Pharmacogenetics and Genomics*, **2009**, 19, 565-6 | 1.9 | 26 |
| 136 | Factors affecting drug concentrations and QT interval during thioridazine therapy. *Clinical Pharmacology and Therapeutics*, **2007**, 82, 555-65 | 6.1 | 26 |
| 135 | Flucloxacillin-induced liver injury. *Toxicology*, **2008**, 254, 158-63 | 4.4 | 25 |
| 134 | CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. *British Journal of Clinical Pharmacology*, **2000**, 50, 77-80 | 3.8 | 24 |
| 133 | rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. *Journal of Hepatology*, **2021**, 74, 20-30 | 13.4 | 24 |
| 132 | Pharmacogenetics of Adverse Drug Reactions. *Advances in Pharmacology*, **2018**, 83, 155-190 | 5.7 | 23 |
| 131 | Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. *Hepatology*, **2010**, 51, 1463-5 | 11.2 | 23 |
| 130 | Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study. *Alcoholism: Clinical and Experimental Research*, **2015**, 39, 836-42 | 3.7 | 22 |
| 129 | Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. *Thrombosis Research*, **2015**, 136, 69-75 | 8.2 | 22 |
| 128 | Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. *Advances in Pharmacology*, **2012**, 63, 137-67 | 5.7 | 22 |
| 127 | The biological activity of retinoids in melanoma cells. Induction of expression of retinoic acid receptor-beta by retinoic acid in S91 melanoma cells. *FEBS Letters*, **1990**, 273, 19-22 | 3.8 | 22 |
| 126 | The impact of simvastatin on warfarin disposition and dose requirements. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 1422-4 | 15.4 | 21 |
| 125 | Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. *International Journal of Cancer*, **2004**, 110, 266-70 | 7.5 | 20 |
| 124 | Candidate gene case-control studies. *Pharmacogenomics*, **2003**, 4, 127-39 | 2.6 | 20 |
| 123 | Genotyping for cytochrome P450 polymorphisms. *Methods in Molecular Biology*, **2006**, 320, 193-207 | 1.4 | 20 |

| | | | |
|---|---|---|---|
| 122 | Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 606-14 | 15.4 | 19 |
| 121 | Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. *Drug Metabolism and Disposition*, **2010**, 38, 1261-6 | 4 | 19 |
| 120 | A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. *Pharmacogenomics*, **2010**, 11, 989-1002 | 2.6 | 19 |
| 119 | CYP2C9 polymorphism and warfarin dose requirements. *British Journal of Clinical Pharmacology*, **2002**, 53, 408-9 | 3.8 | 19 |
| 118 | Genotyping of the CYP 2D6 gene in Norwegian lung cancer patients and controls. *Pharmacogenetics and Genomics*, **1994**, 4, 47???57 | | 19 |
| 117 | Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. *Hepatology*, **2021**, 73, 268-281 | 11.2 | 19 |
| 116 | Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *Journal of Hepatology*, **2021**, 75, 770-785 | 13.4 | 19 |
| 115 | The Relationship between PON1 phenotype and PON1-192 genotype in detoxification of three oxons by human liver. *Drug Metabolism and Disposition*, **2007**, 35, 315-20 | 4 | 18 |
| 114 | Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. *Hepatology*, **2021**, 73, 1920-1931 | 11.2 | 18 |
| 113 | Altered tropomyosin expression in essential hypertension. *Hypertension*, **2003**, 41, 347-54 | 8.5 | 17 |
| 112 | Genetic regulation of warfarin metabolism and response. *Seminars in Vascular Medicine*, **2003**, 3, 231-8 | | 17 |
| 111 | N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population. *International Journal of Toxicology*, **2004**, 23, 25-31 | 2.4 | 17 |
| 110 | Warfarin dose requirement and CYP2C9 polymorphisms. *Lancet, The*, **1999**, 353, 1972-1973 | 40 | 17 |
| 109 | Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls. *Current Drug Metabolism*, **2014**, 15, 196-201 | 3.5 | 17 |
| 108 | Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. *Pharmacogenetics and Genomics*, **1992**, 2, 19-24 | | 16 |
| 107 | A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. *Human Genetics*, **1993**, 91, 616-7 | 6.3 | 16 |
| 106 | Relevance of CYP2E1 to non-alcoholic fatty liver disease. *Sub-Cellular Biochemistry*, **2013**, 67, 165-75 | 5.5 | 15 |
| 105 | Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. *Journal of Clinical Virology*, **2013**, 58, 331-3 | 14.5 | 15 |

| | | | |
|---|---|---|---|
| 104 | Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. *Pharmacogenomics*, **2012**, 13, 1405-17 | 2.6 | 15 |
| 103 | Genetic susceptibility in pancreatic ductal adenocarcinoma. *British Journal of Surgery*, **2008**, 95, 22-32 | 5.3 | 15 |
| 102 | Polymorphisms in immunoregulatory genes: towards individualized immunosuppressive therapy?. *Molecular Diagnosis and Therapy*, **2002**, 2, 13-23 | | 15 |
| 101 | The kinetic mechanism of the major form of ox kidney aldehyde reductase with D-glucuronic acid. *Biochemical Journal*, **1982**, 205, 381-8 | 3.8 | 15 |
| 100 | Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. *Hepatology*, **2021**, 74, 2452-2466 | 11.2 | 15 |
| 99 | An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 767-72 | 15.4 | 14 |
| 98 | Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. *Pharmacogenetics and Genomics*, **1997**, 7, 149-52 | | 14 |
| 97 | Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 178-187 | 6.1 | 13 |
| 96 | Patients benefit from genetics-guided coumarin anticoagulant therapy. *Clinical Pharmacology and Therapeutics*, **2014**, 96, 15-7 | 6.1 | 13 |
| 95 | Is there a need to teach pharmacogenetics?. *Clinical Pharmacology and Therapeutics*, **2014**, 95, 245-7 | 6.1 | 13 |
| 94 | Defining drug response for stratified medicine. *Drug Discovery Today*, **2017**, 22, 173-179 | 8.8 | 13 |
| 93 | Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. *Gastroenterology*, **2011**, 140, 1694-5 | 13.3 | 13 |
| 92 | Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. *Hepatology*, **2002**, 36, 1355-60 | 11.2 | 13 |
| 91 | Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. *Drug Metabolism and Personalized Therapy*, **2015**, 30, 165-74 | 2 | 12 |
| 90 | Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. *Drug Metabolism and Disposition*, **2010**, 38, 1211-7 | 4 | 12 |
| 89 | CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. *Pharmacogenetics and Genomics*, **2012**, 22, 692-4 | 1.9 | 12 |
| 88 | Contribution of CYP2C9 to variability in vitamin K antagonist metabolism. *Expert Opinion on Drug Metabolism and Toxicology*, **2006**, 2, 3-15 | 5.5 | 12 |
| 87 | Purification and properties of cellular retinoic acid-binding protein from neonatal rat skin. *Biochimica Et Biophysica Acta - General Subjects*, **1988**, 965, 118-26 | 4 | 12 |

| | | | |
|---|---|---|---|
| 86 | Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1125-1135 | 6.1 | 12 |
| 85 | Presenilin polymorphisms in Alzheimer's disease. *Lancet, The*, **1997**, 350, 958-9 | 40 | 11 |
| 84 | Development of analytical technology in pharmacogenetic research. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2004**, 369, 133-40 | 3.4 | 11 |
| 83 | Identification and analysis of retinoic acid-binding proteins and receptors from nuclei of mammalian cells. *Methods in Enzymology*, **1990**, 189, 239-47 | 1.7 | 11 |
| 82 | Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. *Journal of Oncology*, **2011**, 2011, 215985 | 4.5 | 10 |
| 81 | Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. *Pancreas*, **2011**, 40, 1289-94 | 2.6 | 10 |
| 80 | The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects. *British Journal of Clinical Pharmacology*, **2000**, 49, 240-3 | 3.8 | 10 |
| 79 | Analysis of cytochrome P450 polymorphisms. *Methods in Molecular Biology*, **1998**, 107, 405-22 | 1.4 | 10 |
| 78 | HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. *Toxicological Sciences*, **2020**, 178, 115-126 | 4.4 | 10 |
| 77 | Genotypes and phenotypes of CYP3A in Bangladeshi population. *Clinica Chimica Acta*, **2011**, 412, 531-6 | 6.2 | 9 |
| 76 | Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. *British Journal of Pharmacology*, **2011**, 162, 989-99 | 8.6 | 9 |
| 75 | A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 1158-9 | 15.4 | 9 |
| 74 | Individualized drug therapy. *Current Opinion in Drug Discovery & Development*, **2007**, 10, 29-36 | | 9 |
| 73 | HLA associations with infliximab-induced liver injury. *Pharmacogenomics Journal*, **2020**, 20, 681-686 | 3.5 | 8 |
| 72 | Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. *Alcohol*, **2018**, 66, 1-7 | 2.7 | 8 |
| 71 | Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. *Pharmacogenetics and Genomics*, **1994**, 4, 159-61 | | 8 |
| 70 | Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 465-472 | 15.4 | 7 |
| 69 | Next-Generation Sequencing of Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. *Frontiers in Genetics*, **2019**, 10, 134 | 4.5 | 7 |

| | | | |
|---|---|---|---|
| 68 | Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. *Toxicology*, **2008**, 253, 10 | 4.4 | 7 |
| 67 | Kinetic studies on the major form of aldehyde reductase in ox kidney: a general kinetic mechanism to explain substrate-dependent mechanisms and the inhibition by anticonvulsants. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **1986**, 1, 163-8 | | 7 |
| 66 | Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. *American Journal of Gastroenterology*, **2021**, 116, 106-115 | 0.7 | 7 |
| 65 | Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. *Aging*, **2016**, 9, 26-40 | 5.6 | 7 |
| 64 | PharmVar GeneFocus: CYP2C9. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 662-676 | 6.1 | 7 |
| 63 | Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 762-8.e1 | 6.9 | 6 |
| 62 | Warfarin sensitivity: be aware of genetic influence. *Age and Ageing*, **2003**, 32, 226-7 | 3 | 6 |
| 61 | HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. *Chemical Research in Toxicology*, **2018**, 31, 1022-1024 | 4 | 6 |
| 60 | Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1123-5 | 15.4 | 5 |
| 59 | Molecular genotyping to predict debrisoquine hydroxylation phenotype. *Lancet, The*, **1990**, 336, 889-90 | 40 | 5 |
| 58 | Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav. *DNA and Cell Biology*, **2020**, 39, 349-354 | 3.6 | 5 |
| 57 | A Role in the Genetic Predisposition to NAFLD-HCC?. *Cancers*, **2021**, 13, | 6.6 | 5 |
| 56 | A trans-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation | | 5 |
| 55 | Endocytosis and Lack of Cytotoxicity of Alkyl-Capped Silicon Quantum Dots Prepared from Porous Silicon. *Materials*, **2019**, 12, | 3.5 | 4 |
| 54 | Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver Injury. *Hepatology Communications*, **2019**, 3, 1032-1035 | 6 | 4 |
| 53 | Polymorphisms in the tropomyosin TPM1 short isoform promoter alter gene expression and are associated with increased risk of metabolic syndrome. *American Journal of Hypertension*, **2010**, 23, 399-404 | 2.3 | 4 |
| 52 | Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. *Journal of Hepatology*, **2021**, | 13.4 | 4 |
| 51 | Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. *JHEP Reports*, **2022**, 4, 100409 | 10.3 | 4 |

| | | | |
|---|---|---|---|
| 50 | A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. *Journal of Hepatology*, **2021**, | 13.4 | 4 |
| 49 | A Genome-Wide Association Study Identifies Potential Susceptibility Loci for Hepatotoxicity Due to Various Drugs. *Gastroenterology*, **2011**, 140, S-886 | 13.3 | 3 |
| 48 | Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. *Science Translational Medicine*, **2021**, 13, eabe8939 | 17.5 | 3 |
| 47 | Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 454-464 | 15.4 | 2 |
| 46 | Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. *Thrombosis Research*, **2015**, 136, 94-100 | 8.2 | 2 |
| 45 | The Effect of the CYP1A1*2A Allele on Colorectal Cancer Susceptibility in a British Population. *Genetic Testing and Molecular Biomarkers*, **2016**, 20, 475-7 | 1.6 | 2 |
| 44 | TM6SF2 as a genetic risk factor for fibrosis. *Hepatology*, **2015**, 62, 1321 | 11.2 | 2 |
| 43 | Pharmacogenetics of Drug Transporters **2012**, 101-148 | | 2 |
| 42 | Pharmacogenetics of oral anticoagulants. *Personalized Medicine*, **2005**, 2, 23-27 | 2.2 | 2 |
| 41 | Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. *Nature Communications*, **2021**, 12, 6233 | 17.4 | 2 |
| 40 | Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. *JHEP Reports*, **2022**, 4, 100477 | 10.3 | 2 |
| 39 | A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. *Nature Genetics*, | 36.3 | 2 |
| 38 | Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury. *Clinical and Translational Allergy*, **2014**, 4, O3 | 5.2 | 1 |
| 37 | Pharmacogenetics of Adverse Drug Reactions **2012**, 295-321 | | 1 |
| 36 | Developments in Analyses in Pharmacogenetic Datasets **2012**, 415-435 | | 1 |
| 35 | Role of Pharmacogenetics in Registration Processes **2012**, 461-475 | | 1 |
| 34 | Pharmacogenetics of cytotoxic drugs. *Expert Review of Anticancer Therapy*, **2001**, 1, 301-8 | 3.5 | 1 |
| 33 | New Opportunities in Cancer Risk Evaluation Using PCR-Based DNA Analysis for CYP2D6. *Environmental Health Perspectives*, **1993**, 101, 117 | 8.4 | 1 |

| | | | |
|---|---|---|---|
| 32 | Nuclear retinoic-acid-binding proteins and receptors in retinoic-acid-responsive cell lines. *Pathobiology*, **1989**, 57, 339-45 | 3.6 | 1 |
| 31 | Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease | | 1 |
| 30 | Pharmacogenomics of Drug-Induced Liver Injury. *Advances in Molecular Pathology*, **2020**, 3, 107-115 | 0.3 | 1 |
| 29 | Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. *British Journal of Clinical Pharmacology*, **2021**, | 3.8 | 1 |
| 28 | Pharmacogenetics of Pain Medication **2012**, 353-374 | | 0 |
| 27 | Drug-Induced Cholestasis: Mechanisms and Importance **2017**, 117-128 | | |
| 26 | Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI). *Methods in Pharmacology and Toxicology*, **2018**, 497-509 | 1.1 | |
| 25 | Point of care testing for improving risk- benefit ratio of aspirin and warfarin. *Molecular Cytogenetics* , **2014**, 7, I54 | 2 | |
| 24 | Pharmacogenomics of Warfarin **2014**, 497-507 | | |
| 23 | Direct-to-consumer pharmacogenomic testing assessed in a US-based study. *Journal of the Royal College of Physicians of Edinburgh, The*, **2014**, 44, 212-3 | 0.9 | |
| 22 | Pharmacogenetics: A Historical Perspective **2012**, 1-12 | | |
| 21 | Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes **2012**, 13-80 | | |
| 20 | Pharmacogenetics of Phase II Drug Metabolizing Enzymes **2012**, 81-100 | | |
| 19 | Pharmacogenetics of Drug Targets **2012**, 149-182 | | |
| 18 | Pharmacogenetics in Cancer **2012**, 251-270 | | |
| 17 | Cardiovascular Pharmacogenetics **2012**, 183-213 | | |
| 16 | Pharmacogenetics in Psychiatry **2012**, 215-250 | | |
| 15 | Pharmacogenetics of Asthma and COPD **2012**, 271-294 | | |

| | | |
|---|---|---|
| 14 | Pharmacogenomics of Inflammatory Bowel Diseases **2012**, 323-351 | |
| 13 | Ethical and Social Issues in Pharmacogenomics Testing **2012**, 375-400 | |
| 12 | Applications of Pharmacogenetics in Pharmaceutical Research and Development **2012**, 437-460 | |
| 11 | Genetic Predisposition to NAFLD and NASH: Implications for Pathogenesis, Diagnosis, Prevention, and Management **2013**, 157-170 | |
| 10 | Genetic Factors in the Pathogenesis of Drug-Induced Liver Injury **2013**, 215-225 | |
| 9 | High-Throughput Genotyping Technologies for Pharmacogenetics **2012**, 401-414 | |
| 8 | Pharmacogenomics Applications in Drug Metabolism. *Methods in Pharmacology and Toxicology*, **2008**, 109-120 | 1.1 |
| 7 | Relevance of PXR to Flucloxacillin-induced Liver Injury. *Toxicology*, **2008**, 253, 2 | 4.4 |
| 6 | Nash is A Genetically Determined Disease66-75 | |
| 5 | Cellular retinoic acid-binding protein from neonatal rat skin: purification and analysis. *Methods in Enzymology*, **1990**, 189, 307-14 | 1.7 |
| 4 | Pharmacogenomics **2003**, 76-89 | |
| 3 | Genetic risk factors for DILI-recent findings from large international networks. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, SY76-2 | 0 |
| 2 | Pharmacogenetics: Possibilities and Pitfalls477-483 | |
| 1 | Genetic Polymorphism of Drug-Metabolizing Enzymes and Drug Transporters in Drug Toxicity **2021**, 139-165 | |